Open AccessNavigating treatment approaches for presumed ESBL-producing infections
Author(s) -
Pranita D. Tamma,
Amy J Mathers
Publication year - 2021
Publication title -
jac-antimicrobial resistance
Language(s) - English
Resource type - Journals
ISSN - 2632-1823
DOI - 10.1093/jacamr/dlaa111
Subject(s) - klebsiella pneumoniae , carbapenem , antimicrobial , ceftriaxone , antibiotic resistance , medicine , intensive care medicine , drug resistance , microbiology and biotechnology , antibiotics , biology , escherichia coli , biochemistry , gene
ESBL-producing Enterobacterales (ESBL-E) remain a significant global threat. In several regions of the world, ESBLs are produced by over half of Escherichia coli or Klebsiella pneumoniae infections, contributing to significant morbidity and mortality. Though it is accepted that carbapenems are effective for the treatment of invasive ESBL-E infections, controversy remains as to whether carbapenem alternatives can be considered in select cases. Indiscriminate carbapenem use for the treatment of ESBL-E infections will likely further the international antimicrobial resistance crisis, underscoring the importance of investigating the role of non-carbapenem options. In this issue of JAC-Antimicrobial Resistance , we present a PRO/CON debate exploring whether carbapenems are necessary for all infections caused by ceftriaxone-resistant Enterobacterales.